ERBB2 and breast carcinoma: Olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor which is used as a targeted therapy for gBRCAm, provided a significant benefit over standard therapy among patients with HER2-negative breast cancer, regardless of age [20, 21].